According to the agreement, Laureate will produce Tolera’s TOL101 monoclonal antibody under current good manufacturing practice (cGMP) conditions to be used in clinical trials.
John Puisis, president and CEO of Tolera, said: “We are excited to work with Laureate, a company with demonstrated expertise in biopharmaceutical manufacturing. Their capabilities in both clinical and commercial-grade materials can support our aggressive development and commercial plans. We look forward to our partnership with Laureate in utilizing their specialized experience in the manufacture of monoclonal antibodies.”